Answers are grounded in this paper and cite their sources.
Objective Aggregate scores on the Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder-7 (GAD-7) may conceal differences in symptom-level change during residential substance use disorder (SUD) treatment. This study examined whether improvements in total scores concealed differential symptom change and residual burden.Method Routine item-level data from 98 adult treatment episodes were assessed a median of 20 days apart. After descriptive reconnaissance, a timestamped analysis plan was frozen before definitive modelling. Cumulative-logit generalised estimating equations tested Time × Item interactions; secondary analyses examined residual endorsement, complete resolution, threshold dependence and prespecified sensitivities.Results Change differed across PHQ-9 items, Wald χ2(8) = 27.32, Holm-adjusted p = .001, and GAD-7 items, Wald χ2(6) = 18.42, Holm-adjusted p = .005; both findings remained significant across all executable prespecified sensitivity analyses. PHQ-9 ordinal shifts ranged from OR = 10.37 for concentration difficulty to 37.37 for anhedonia, and GAD-7 shifts from 6.40 for irritability to 19.01 for trouble relaxing. Residual fatigue (40.8%), sleep disturbance (37.8%), nervousness (42.9%), uncontrollable worry (38.8%) and irritability (37.8%) remained common at discharge.Conclusions Aggregate improvement concealed non-uniform symptom change and residual burden. Item-level review may add clinically specific information to validated totals without treating individual items as diagnostic measures.
No takes yet. Share an insight, caveat, or question.
Lomas et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: